Examples of 'eculizumab' in a sentence
Meaning of "eculizumab"
Eculizumab: A medication used for treating certain blood disorders and diseases of the immune system
Show more definitions
- A monoclonal antibody directed against the complement protein C5.
How to use "eculizumab" in a sentence
Basic
Advanced
eculizumab
Coordination of eculizumab use through an expert centre.
Statement that the patient is receiving eculizumab.
It is unknown whether eculizumab is excreted into human milk.
Soliris contains the active substance eculizumab.
Eculizumab has been shown to alter the course of aHUS.
The development of breathing difficulty was prevented by eculizumab.
Eculizumab completely prevented this effect.
It contains the active substance eculizumab.
Said eculizumab may be administered chronically.
The risk of developing antibodies to eculizumab.
It is not known whether eculizumab is secreted into human milk.
The risks of treatment with eculizumab.
The volume of distribution of eculizumab in humans approximates that of plasma.
Said whole antibody may be eculizumab.
Eculizumab should be given to a pregnant woman only if clearly needed.
See also
The safety profile of eculizumab is unclear.
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
Animal reproduction studies have not been conducted with eculizumab.
In addition eculizumab is used in the treatment of patients with aHUS.
Isoelectric profiling was then performed on the purified eculizumab samples.
Eculizumab showed a higher proportion of patients with transfusion independence.
All patients being treated with eculizumab receive a patient safety card.
Eculizumab appears to be useful for atypical hemolytic uremic syndrome aHUS.
We included trials comparing eculizumab with placebo or best available therapy.
Eculizumab has been proven to be effective in the treatment of nocturnal paroxistic hemoglobinuria.
Transplantation protocols are advocating the use of eculizumab in patients with aHUS.
Eculizumab is a humanized monoclonal antibody that acts as a terminal complement inhibitor.
On treatment with eculizumab.
Eculizumab binds to and inhibits a specific protein in the body that causes inflammation.
A national protocol for starting and stopping eculizumab for clinical reasons.
No animal studies have been conducted to evaluate the genotoxic and carcinogenic potential of eculizumab.
The isoelectric profile of the resulting purified eculizumab was determined using isoelectric focusing.
No pediatric or adolescent participants required new dialysis during treatment with eculizumab.
Results are compared with those obtained with eculizumab using the same assays.
Eculizumab contains only naturally occurring amino acids and has no known active metabolites.
The requirement to vaccinate children against pneumococcus and haemophilus before eculizumab treatment.
All healthcare practitioners who may prescribe eculizumab receive the appropriate educational material.
The eculizumab blocks a blood protein that causes the breakdown of red blood cells.
Drug interaction studies have not been conducted with eculizumab in patients treated with IVIg.
Eculizumab inhibits terminal complement activation and therefore makes people vulnerable to infection with encapsulated organisms.
The need for children to be vaccinated against pneumococcus and haemophilus before eculizumab treatment.
Eculizumab is a recently tested experimental treatment in NMO.
We identified one study that included a limited number of patients comparing eculizumab with placebo.
Fertility No specific study of eculizumab on fertility has been conducted.
There is an important risk of Aspergillus infection in patients treated with eculizumab.
Eculizumab prevented such high grade of twitching with only a median score of I being observed FIG.
PNH medical history was similar between ravulizumab and eculizumab treatment groups.
Eculizumab has recently been approved for use in NMO in both the US and Europe.
An additional example of a reference isoelectric profile for eculizumab is described in the Examples.
Said eculizumab may be administered once every 2 weeks.
